Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
05:07pm, Friday, 22'nd Mar 2024
Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite
David Roche says India won't replace China in global trade
04:00am, Friday, 22'nd Mar 2024
David Roche, president and global strategist at Independent Strategy, says China may be stagnating, but it's "stagnating at a later stage of development than India."
Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek
09:01am, Wednesday, 13'th Mar 2024
Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.
Roche explores selling lung disease drug, Bloomberg reports
11:54am, Monday, 26'th Feb 2024
Roche is considering selling its lung disease drug Esbriet, Bloomberg News reported on Monday citing people with knowledge of the matter.
David Roche: Market's expectation that AI will revolutionize productivity will 'run out of fizz'
04:00am, Monday, 26'th Feb 2024
David Roche, president and global strategist at Independent Strategy, says the market expects artificial intelligence to "revolutionize productivity" in the U.S. economy, but that narrative will event
Roche's Xolair reduces reactions to severe food allergies in study
01:51pm, Sunday, 25'th Feb 2024
Xolair, a 20-year-old asthma drug sold by Roche and Novartis , significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sun
Move Over Magnificent 7, Say Hello to the GRANOLAS
06:10am, Thursday, 22'nd Feb 2024
There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
02:36pm, Monday, 19'th Feb 2024
Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
Roche: The Recent Sell-Off Created A 30% Upside Potential
07:04am, Sunday, 11'th Feb 2024
Roche is a well-recognized pharmaceutical company with a strong international presence and a market capitalization of CHF 187 billion. Despite recent challenges, Roche's 2024 guidance shows potential
Roche cutting 345 jobs in product development - media
01:16am, Friday, 09'th Feb 2024
Roche is cutting 345 jobs, Swiss website Muula reported, as the drugs company responds to lower profit posted for 2023 and a more cautious outlook for the year ahead.
Roche Holding AG (RHHBY) Q4 2023 Earnings Call Transcript
10:52pm, Thursday, 01'st Feb 2024
Roche Holding AG (RHHBY) Q4 2023 Earnings Call Transcript
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
03:36pm, Thursday, 01'st Feb 2024
Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.
Roche forecasts return to growth in 2024 as it overcomes drop in COVID sales
01:30am, Thursday, 01'st Feb 2024
Roche said on Thursday that 2024 would see a return to sales growth as it is overcoming a slump in demand for its COVID-19 products and the sales decline of a trio of established cancer drugs is abati
Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU
01:32pm, Tuesday, 16'th Jan 2024
Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.
Roche Pharmaceuticals CEO Teresa Graham talks innovation, and changing the standard of care
12:00pm, Saturday, 13'th Jan 2024
Speaking at the JPMorgan Healthcare Conference, Roche Pharmaceuticals (RHHBY) CEO Teresa Graham discusses the company's innovation focus and outlook with Yahoo Finance's Anjalee Khemlani. Graham says
